Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition. - Kam NW; Lau JYH; Lau CY; Lam TC; Chan KSK; Dai W; Fun VLH; Chiang CL; Kwong DLW (Clinical and translational medicine, 2025)